Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Down – Here’s What Happened

Posted by Paula Ricardo on Oct 8th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report)’s share price gapped down prior to trading on Thursday. The stock had previously closed at $12.19, but opened at $11.63. Fresenius SE & Co. shares last traded at $11.6825, with a volume of 18,360 shares.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Read Our Latest Research Report on Fresenius SE & Co.

Fresenius SE & Co. Stock Down 4.3%

The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $26.27 billion, a price-to-earnings ratio of 14.76 and a beta of 0.60. The firm’s 50-day simple moving average is $13.16 and its 200-day simple moving average is $12.37.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to analyst estimates of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Sell-side analysts forecast that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.